INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On March14, 2017, Intellia Therapeutics, Inc. issued a press
release announcing its financial results for the year and three
months ended December31, 2016 (the Press Release). A copy of the
Press Release is furnished herewith as Exhibit 99.1.
The information in this report furnished to Item2.02 shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section. It may only be
incorporated by reference in another filing under the Exchange
Act or the Securities Act of 1933, as amended, if such subsequent
filing specifically references the information furnished to
Item2.02 of this report.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Press release dated March14, 2017 |
About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue. INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Recent Trading Information
INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) closed its last trading session up +0.18 at 14.29 with 122,669 shares trading hands.